Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Products under Development by Stage of Development | 7 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Products under Development by Therapy Area | 8 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Products under Development by Indication | 9 | 2 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Products under Development by Companies | 13 | 2 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Companies Involved in Therapeutics Development | 21 | 5 |
| Ampio Pharmaceuticals, Inc. | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Cyano Biotech GmbH | 23 | 1 |
| Lixte Biotechnology Holdings, Inc. | 24 | 1 |
| Signum Biosciences, Inc. | 25 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Drug Profiles | 26 | 10 |
| Drugs to Activate PP2A for Oncology Drug Profile | 26 | 1 |
| DT-1154 Drug Profile | 27 | 1 |
| LB-100 Drug Profile | 28 | 3 |
| NCE-001 Drug Profile | 31 | 1 |
| Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease Drug Profile | 32 | 1 |
| Small Molecules to Inhibit PP1 and PP2A for Oncology Drug Profile | 33 | 1 |
| VEL-015 Drug Profile | 34 | 2 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Dormant Projects | 36 | 1 |
| Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Featured News &Press Releases | 37 | 7 |
| Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression | 37 | 1 |
| Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity | 37 | 1 |
| Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds | 38 | 1 |
| Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies | 38 | 1 |
| Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 | 39 | 1 |
| Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch | 39 | 1 |
| Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer | 40 | 1 |
| Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100 | 41 | 1 |
| Jul 31, 2012: Lixte Biotechnology Announces Increased Funding And FDA Allowance To Conduct Phase I Trial Of LB-100 | 41 | 1 |
| Jul 16, 2012: Ampio Pharma Advances NCE001 Cancer Drug Into Preclinical Development | 41 | 1 |
| May 01, 2012: Lixte Submits Investigational New Drug Application To FDA For Approval Of Clinical Trial Of LB-100 | 42 | 1 |
| Sep 22, 2011: Lixte Biotechnology Receives US Patent For LB-100 | 42 | 1 |
| Oct 05, 2010: Lixte Collaborates With NCI For Clinical Evaluation Of LB-100 | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |
